Form 13-F position report

OUTLOOK THERAPEUTICS INC COM N

Reported by MORGAN STANLEY

OTLK CUSIP 69012T206 Manager CIK 0000895421

Reported 49,586 shares, down 2,202 (4.3%) from the prior quarter.

Reported value -45.2%; share count -4.3% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 49,586 Quarter-end amount reported
Reported value $51,000 Fair value at quarter end
Consecutive quarters held 7 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 54000
2022-03-31 93000
2022-06-30 51000
2022-09-30 74000
2022-12-31 102765
2023-03-31 175186
2023-06-30 350093
2023-09-30 32046
2023-12-31 198762
2024-03-31 142958
2024-03-31 0
2024-06-30 95098
2024-09-30 233512
2024-12-31 108470
2025-03-31 48158
2025-06-30 680958
2025-09-30 821
2025-12-31 9518
2026-03-31 783
2026-06-30 26960
2026-09-30 25847

Quarterly position history

How this manager's reported quarter-end position changed over time.

21 quarters
Quarterly reported position history for OUTLOOK THERAPEUTICS INC COM N held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 45,069 +28,113 (165.8%) < 0.01% $25,847 2026-11-13
Q2 2026 Added 16,956 +13,150 (345.5%) < 0.01% $26,960 2026-08-13
Q1 2026 Reduced 3,806 -2,218 (-36.8%) < 0.01% $783 2026-05-15
Q4 2025 Added 6,024 +5,249 (677.3%) < 0.01% $9,518 2026-02-13
Q3 2025 Reduced 775 -424,824 (-99.8%) < 0.01% $821 2025-11-14
Q2 2025 Added 425,599 +386,125 (978.2%) < 0.01% $680,958 2025-08-15
Q1 2025 Reduced 39,474 -17,918 (-31.2%) < 0.01% $48,158 2025-05-15
Q4 2024 Added 57,392 +13,663 (31.2%) < 0.01% $108,470 2025-02-14
Q3 2024 Added 43,729 +30,843 (239.4%) < 0.01% $233,512 2024-11-14
Q2 2024 Added 12,886 +913 (7.6%) < 0.01% $95,098 2024-08-14
Q1 2024 Reduced 0 -504,471 (-100.0%) 0 $0 2024-05-15
Q1 2024 New 11,973 +11,973 (0.0%) < 0.01% $142,958 2024-05-15
Q4 2023 Added 504,471 +359,467 (247.9%) < 0.01% $198,762 2024-02-13
Q3 2023 Reduced 145,004 -56,199 (-27.9%) < 0.01% $32,046 2023-11-15
Q2 2023 Added 201,203 +40,482 (25.2%) < 0.01% $350,093 2023-08-14
Q1 2023 Added 160,721 +65,569 (68.9%) < 0.01% $175,186 2023-05-15
Q4 2022 Added 95,152 +33,687 (54.8%) < 0.01% $102,765 2023-02-14
Q3 2022 Added 61,465 +11,879 (24.0%) < 0.01% $74,000 2022-11-14
Q2 2022 Reduced 49,586 -2,202 (-4.3%) < 0.01% $51,000 2022-08-15
Q1 2022 Added 51,788 +12,325 (31.2%) < 0.01% $93,000 2022-05-13
Q4 2021 Reduced 39,463 -195,464 (-83.2%) < 0.01% $54,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

88 managers reported OUTLOOK THERAPEUTICS INC COM N for Q2 2022.

Managers reporting OUTLOOK THERAPEUTICS INC COM N in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 6,955,607 +275,491 < 0.01% $7,094,000 6 qtrs
VANGUARD GROUP INC Reduced 5,619,636 -16,483 < 0.01% $5,731,000 14 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 2,057,809 +193,204 < 0.01% $2,098,000 13 qtrs
STATE STREET CORPORATION Added 1,889,339 +222,270 < 0.01% $1,927,000 5 qtrs
LVW Advisors LLC Reduced 1,733,633 -10,000 0.36% $1,768,000 13 qtrs
VISTA FINANCE LLC Added 1,020,370 +36,725 1.36% $1,041,000 2 qtrs
NORTHERN TRUST CORPORATION Reduced 974,901 -6,584 < 0.01% $995,000 10 qtrs
Nuveen Asset Management LLC Reduced 826,914 -117,905 < 0.01% $843,000 5 qtrs
TWO SIGMA ADVISERS LP Reduced 350,100 -191,200 < 0.01% $357,000 8 qtrs
THE BANK OF NEW YORK MELLON CORPORATION Reduced 331,949 -462 < 0.01% $339,000 10 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
11,613
Shared
0
None
37,973

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.